Continuous glucose monitoring may lower mortality risk in diabetic patients on insulin
Research presented at the EASD meeting indicates that type 2 diabetes patients using continuous glucose monitoring (CGM) while on basal insulin have a significantly lower risk of mortality. The study suggests that CGM technology helps patients better manage glucose levels and reduce long-term complications.
Why it matters
This evidence supports the clinical adoption of CGM technology as a life-saving tool for insulin-dependent diabetes patients.
by European Association for the Study of Diabetes
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Pixabay/CC0 Public Domain People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% lower risk of dying from any cause after one year than those who did not use CGM, according to an analysis of patient data being presented at the annual meeting of the European Association for the Study of Diabetes ( EASD ) in Milan, Italy, Sept. 28–Oct. 2. After two years, their risk was 35% lower.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in